Clinical trial
Iressa/Docetaxel in Non-Small-Cell Lung Cancer
NCT00048087 · M.D. Anderson Cancer Center, Other · Withdrawn
Key facts
| NCT number | NCT00048087 |
|---|---|
| Title | Iressa/Docetaxel in Non-Small-Cell Lung Cancer |
| Official title | A Phase II Study of ZD1839 (Iressa), Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor, in Combination With Docetaxel in Patients With Recurrent or Metastatic Advanced Non-Small Cell Lung Cancer |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | AstraZeneca Industry Aventis Pharmaceuticals |
| Status | Withdrawn |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Non-small Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | ZD1839, Docetaxel |
| Enrollment | 0 |
| Start date | Aug 1, 2002 |
| Primary completion | Jul 1, 2003 |
| Completion | Jul 1, 2003 |
| First posted | Oct 25, 2002 |
| Last update posted | Jul 31, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: